Introduction
============

Cardiac fibroblasts are fundamentally involved in cardiac remodelling in normal ageing heart \[[@b1]\] and in damaged myocardium \[[@b2]\]. Aberrant proliferation of fibroblasts and their transformation to myofibroblasts is a hallmark of cardiac fibrosis, which is characterized by excessive extracellular matrix built-up leading to loss of tissue compliance \[[@b3], [@b4]\]. Because of their wide-ranging participation in myocardial pathophysiology, cardiac fibroblasts represent an attractive target in managing cardiac disorders, including cardiac hypertrophy, heart failure and arrhythmias \[[@b5]\]. Indeed, atrial fibrosis has been closely associated with atrial fibrillation \[[@b6], [@b7]\] and sinus node dysfunction \[[@b8]\].

Hydrogen sulphide (H~2~S) is an endogenously generated gaseous transmitter that has been reported to attenuate cardiac fibrosis \[[@b9]\]. It is known to mediate its effects by modulating ion channel activity in many cellular systems \[[@b10]\]. Hydrogen sulphide was the first opener of K~ATP~ channel identified in vascular smooth muscle cells \[[@b11]\]. Through activation of K~ATP~ channels, H~2~S lowers blood pressure, protects heart from ischaemia and reperfusion injury \[[@b12], [@b13]\]. We have recently reported that H~2~S inhibited delayed rectifier potassium channels in human iPS--derived cardiomyocytes \[[@b14]\]. Yet, effect of H~2~S on cardiac fibroblasts remains poorly understood. We hypothesized that H~2~S inhibits proliferation of atrial fibroblasts by inhibiting functioning of potassium channels. We present supporting data that H~2~S may potentially modulate cardiac fibrosis by inhibiting BK~Ca~, I~to~ and IK~ir~, independent of K~ATP~ channels, leading to decreased proliferation and suppression of transforming growth factor-β1 (TGF-β1)--induced myofibroblast transformation of atrial fibroblasts.

Materials and methods
=====================

Fibroblast isolation
--------------------

Patients undergoing mitral valve repair and coronary bypass surgery (*n* = 10) were recruited after informed consent in protocol approved by institutional review board of Singapore General Hospital that conformed to the Declaration of Helsinki. Atrial appendages were collected as surgical by-product. Human atrial fibroblasts were isolated by mincing the appendages to less than 1 mm^3^ and followed by 0.1% trypsin digestion for 20 min. before plating onto tissue culture--treated 60-mm dishes to produce fibroblastic outgrowth from minced tissue pieces. The isolated fibroblasts were confirmed with expression of collagen I (1/20; Southern Biotech, Birmingham, AL, USA) and anti-human fibroblast (1/1000; Sigma-Aldrich, St. Louis, MO, USA) antibodies ([Fig. S1](#SD1){ref-type="supplementary-material"}). Atrial fibroblasts were passaged as monolayer in 10% foetal bovine serum--supplemented DMEM. Fibroblasts between passage 1 and 3 were used for subsequent experiments.

Electrophysiological recordings
-------------------------------

Cell were placed on the stage of a Nikon Diaphot inverted microscope and superfused continuously at 36 ± 1°C with Tyrode solution containing (in mM) 140 NaCl, 5.4 KCl, 1.8 CaCl~2~, 1 MgCl~2~, 10 HEPES and 10 Glucose (pH adjusted to 7.4 with NaOH). The patch-clamped cell was superfused by means of a temperature-controlled micro-superfusor (TC-324B, Warner Instruments, Hamden, CT, USA). Patch pipettes were made from borosilicate glass shanks (Sutter Instrument, Novato, CA, USA) and pulled with a Brown--Flaming puller (Model P-97; Sutter Instrument Co), and had tip resistances of 2--3 MΩ when filled with pipette solution. Pipette tips were polished (Microforge MF830; Narishige, Tokyo, Japan). These patch pipettes were filled with a standard solution containing (in mM) 140 KCl, 1.2 MgCl~2~, 0.05 EGTA, 10 HEPES, 0.1 GTP and 5.0 Mg ATP (pH adjusted to 7.2 with KOH). For Na^+^ current recording, the patch pipettes were filled with (in mM) 35 NaCl, 105 CsF, 0.1 EGTA and 10 HEPES (pH adjusted to 7.4 with CsOH). After a gigaohm seal was obtained by negative pressure suction, the cell membrane was ruptured by a gentle suction to establish whole-cell configuration with a seal resistance \>800 MΩ. The cell membrane capacitance (40.27 ± 8.2 pF) was electrically compensated with the pulse software. The series resistance (Rs, 3--5 MΩ) was compensated by 50--70% to minimize voltage errors. Currents were elicited with voltage protocols as described in the following results section for different individual current recordings. Whole-cell voltage-clamp experiments were performed with an Axopatch 200B amplifier (Axon Instruments, Foster City, CA, USA) interfaced to a Digidata 1322A data acquisition system controlled by Clampex version 8.1 software (Axon Instruments). Data were analysed with pCLAMP software (Version 10.0; Axon Instrument) and Origin 8.0 (OriginLab, Northampton, MA, USA).

Cell proliferation and apoptosis assay
--------------------------------------

Cell proliferation assay was performed with BrdU kit (Roche, Basel, Switzerland). Briefly, cells were plated on 96-well plate at a density of 3000/well and cultured for 24 hrs. After 4 hrs of serum starvation, cells were incubated for 24 hrs with medium containing ion channel blockers, NaHS or growth factors. BrdU labelling solution (100 μM) diluted 10 times in DMEM (0.1% FBS) was added to each well and the plates were incubated at 37°C for an additional 2 hrs. Incorporated BrdU was detected by an anti-BrdU antibody for 90 min. and colorimetric development proceeded for 15 min. before analysis by ELISA plate reader (SpectraMax, Molecular Device, Sunnyvale, CA, USA). Cellular apoptosis assay was performed with Caspase-3 Fluorescence Assay kit as instructed (Cayman Chemical, Ann Arbor, MI, USA). Briefly, cells were plated on 96-well plate at a density of 10^4^/well and cultured for 24 hrs. After 4 hrs of serum starvation, cells were incubated for 24 hrs with medium containing NaHS. Fluorescent intensity was obtained with ELISA plate reader (SpectraMax, Molecular Device) at 485 nm excitation and 535 nm emission wavelengths.

RNA isolation and RT-PCR
------------------------

Total RNA was extracted from human atrial fibroblasts with Trizol reagent (Life Technologies, Carlsbad, CA, USA) after 12 hrs of treatment. RT-PCR was performed with one-step kit (Invitrogen) where 1 μg RNA and random hexamer primer were used for the initiation of cDNA synthesis. Gene-specific primers for the BK~Ca~ (KCa1.1): forward 5′- GGAGGATGCCTCGAATATCA-3′; reverse 5′-AGCTCGGGATGTTTAGCAGA-3′; I~to~ (Kv4.3): forward 5′-CTGGACAAGAACCAGCGACAGTGCG-3′; reverse 5′-ATCACGATCAGGAGGGCCACATAGGG-3′ and IK~ir~ (Kir2.1): forward, 5′-TTGAGACCCAGACAACCATAGGCTATGG-3′; reverse 5′-TGGCCATGACTGCGCCAATGATG-3′; α-SMA: forward 5′-CATCACCAACTGGGACGACA-3′; reverse 5′-GTGGGTGACACCATCTCCAG- 3′; CSE: forward 5′-TCCGGATGGAGAAACACTTC-3′; reverse 5′-GCTGCCTTTAAAGCTTGACC-3′; K~ATP~ (Kir6.2): forward 5′-GACCCTCATCTTCAGCAAGC-3′; reverse 5′-GGTGTTGCCAAACTTGGAGT-3′; β-actin: forward 5′-TTTGAGACCTTCAACACCCC-3′; reverse 5′-TTTCGTGGATGCCACAGGA-3′. PCR products were fractionated on 2% agarose gel electrophoresis. Data were expressed as values of optical density (OD) standardized to those of β-actin.

Immunocytochemistry
-------------------

Atrial fibroblasts cultured on LabTek chamber slides (Nunc; Thermo Fisher Scientific, Waltham, MA, USA) were fixed with 4% paraformaldehyde, permeabilized with 0.5% Triton-X100 and blocked with 2% BSA. Cells were incubated overnight with antibodies against α-smooth muscle actin (1/2000; α-SMA; Sigma-Aldrich) to identify myofibroblasts, against anti-Kv1.1 (1/1000; Abcam, Cambridge, UK), anti-Kv4.3 (1/500; Abcam) and anti-Kir2.1 (1/1000; Abcam) to identify BK~Ca~, I~to~ and IK~ir~ channels, respectively ([Fig. S2](#SD2){ref-type="supplementary-material"}), before incubating with Alexa Fluor 488 or 555 secondary antibody (Life Technologies) and mounted in Vectashield mounting media containing DAPI for nuclear counterstain.

Statistical analysis
--------------------

Data were expressed as mean ± SE. Statistical significance of the difference between groups was determined with Student\'s *t*-test. A value of *P* \< 0.05 was considered statistically significant.

Results
=======

Hydrogen sulphide suppresses ion currents in human atrial fibroblasts
---------------------------------------------------------------------

Multiple ionic channels are reported to be expressed in human cardiac ventricular fibroblasts \[[@b15]\], ionic channels in our atrial fibroblasts were activated by depolarization voltage between −70 and +60 mV from a holding potential of −80 mV (0.2 Hz) to elicit total outward K^+^ currents. Activated currents that were sensitive to paxilline (1 mM), a specific BK~Ca~ inhibitor, were significantly suppressed at +60 mV, confirming the presence of BK~Ca~ current (52%; 163/309 cells) in human atrial fibroblasts ([Fig. 1](#fig01){ref-type="fig"}A). Under identical voltage-clamp condition, exposure to 100 μM NaHS (as a donor of H~2~S) similarly reduced the peak current density of BK~Ca~ ([Fig. 1](#fig01){ref-type="fig"}B). The inhibitory effects observed could not be washed out ([Fig. 1](#fig01){ref-type="fig"}C). The presence of NaHS resulted in a voltage-dependent suppression of the I--V curve from 10.5 ± 1.2 pA/pF to 6.8 ± 0.9 pA/pF at +40 mV (*P* \< 0.01; *n* = 6) ([Fig. 1](#fig01){ref-type="fig"}D) and a dose-dependent inhibition of BK~Ca~ peak current density with an IC~50~ of 69.4 μM ([Fig. 1](#fig01){ref-type="fig"}E).

![Effect of NaHS on BK~Ca~ currents in human atrial fibroblasts. (**A**) Voltage-dependent current was suppressed by BK~Ca~ blocker Paxilline (1 μM). Paxilline-sensitive I--V relationships of the membrane currents of typical BK~Ca~ channel. (**B**) BK~Ca~ traces recorded in the absence and presence of NaHS (100 μM). (**C**) Time course of BK~Ca~ current inhibition in human atrial fibroblast after addition of NaHS (100 μM). (**D**) Mean I--V relationship of peak BK~Ca~ current in the absence and presence of NaHS (100 μM) (\*\**P* \< 0.01; \**P* \< 0.05 *versus* control). (**E**) A concentration response curve of NaHS-induced inhibition on BK~Ca~. (**F**) Effect of NaHS (100 μM) on BK~Ca~ currents in the presence of Naringenin (10 μM). (**G**) Summarized data for peak BK~Ca~ currents at +40 mV at baseline, in the presence of Naringenin (10 μM), and in the presence of NaHS (100 μM) (\**P* \< 0.05 *versus* basal levels; ^\#^*P* \< 0.05 *versus* Naringenin alone; *n* = 6). (**H**) Plot of the activation τ (τ~act~) as a function of membrane potential in the presence of Naringenin (10 μM) and Naringenin together with NaHS (100 μM) (\*\**P* \< 0.01 *versus* basal levels; ^\#^*P* \< 0.05 *versus* Naringenin alone; *n* = 6).](jcmm0017-1345-f1){#fig01}

To verify the specificity of H~2~S inhibition on BK~Ca~, we assessed its effect in the presence of naringenin (10 μM), a specific opener of BK~Ca~ \[[@b16]\]. BK~Ca~ currents were elicited with clamp pulses at +40 mV from a holding potential of −80 mV under control condition ([Fig. 1](#fig01){ref-type="fig"}F). Compared with baseline (9.9 ± 0.8 pA/pF), naringenin increased BK~C~a current significantly (14.1 ± 0.5 pA/pF; *P* \< 0.01; *n* = 6), but addition of NaHS returned naringenin-induced current to baseline (9.2 ± 0.4 pA/pF; *P* \< 0.05; *n* = 6) ([Fig. 1](#fig01){ref-type="fig"}G). The rising phase of the BK~Ca~ currents at 50 mV with activation τ (τ~act~) at baseline (15.4 ± 0.1 ms) was lowered significantly by naringenin (8.6 ± 0.2 ms; *P* \< 0.01; *n* = 6), but reversed to baseline after addition of NaHS (15.4 ± 0.2 ms; *P* \< 0.05; *n* = 6), which confirmed its modulation of BK~Ca~ channel kinetics ([Fig. 1](#fig01){ref-type="fig"}H).

Similarly, under conditions to elicit total outward K^+^ currents, a 4-aminopyridine (4-AP; 0.5 mM)--sensitive current was detected, indicating the presence of transient outward currents, I~to~ (34%; 104/309 cells) in the atrial fibroblasts ([Fig. 2](#fig02){ref-type="fig"}A). Under identical voltage-clamp condition, exposure of fibroblasts to 100 μM NaHS reduced the peak current density of I~to~ ([Fig. 2](#fig02){ref-type="fig"}B). The inhibitory effects occurred within 1 min., reached saturation by 10 min. and could not be washed out ([Fig. 2](#fig02){ref-type="fig"}C). Addition of NaHS showed a voltage-dependent suppression of the I~to~ current in the I--V curve from 18.2 ± 1.5 pA/pF to 12.7 ± 1.7 pA/pF at +40 mV (*P* \< 0.05; *n* = 6) ([Fig. 2](#fig02){ref-type="fig"}D) and demonstrated a dose-dependent inhibition of peak current density with an IC~50~ of 55.1 μM ([Fig. 2](#fig02){ref-type="fig"}E).

![Effect of NaHS on I~to~ currents in human atrial fibroblasts. (**A**) Transient outward current was activated in traces recorded in the absence and presence of 4-AP (0.5 mM). 4-AP--sensitive I--V relationships of the membrane current of typical I~to~ channel. (**B**) I~to~ traces recorded in the absence and presence of NaHS (100 μM). (**C**) Time course of I~to~ current inhibition in human atrial fibroblast after addition of NaHS (100 μM). (**D**) Mean I--V relationship of peak I~to~ in the absence and presence of NaHS (100 μM) (\**P* \< 0.05 *versus* control). (**E**) A concentration response curve of NaHS-induced inhibition on I~to~. (**F**) Mean voltage-dependent activation of I~to~ current and inactivation (**G**) and time-dependent recovery (**H**) in the absence and presence of NaHS (100 μM) (\**P* \< 0.05 *versus* control). (**I**) Effect of NaHS (100 μM) on I~to~ currents in the presence of NS5806 (10 μM). (**J**) Summarized data for I~to~ at +40 mV at baseline, in the presence of NS5806 (10 μM), and in the presence of NS5806 together with NaHS (100 μM) (\*\**P* \< 0.01 *versus* basal levels; ^\#\#^*P* \< 0.01 *versus* NS5806 alone; *n* = 6). (**K**) Mono-exponential functions were fitted to the current decays, and the time constants τ are shown as a function of membrane potential in the presence of NS5806 (10 μM) and in the presence of both NS5806 and NaHS (100 μM).](jcmm0017-1345-f2){#fig02}

Steady-state activation of I~to~ was unaffected by NaHS ([Fig. 2](#fig02){ref-type="fig"}F). \[The curves were fitted by the Boltzman equation: G/G~max~=1/\[1 + exp(V~T~ − V~1/2~/κ)\], where G/G~max~ represents a ratio of conductance to the maximum conductance, and V~T~ represents the values of the depolarizing pulses\]. The half-maximum activation voltage (V~1/2~) and slope factor under control condition were 17.2 ±1.5 mV and 19.3 ± 1.3, respectively, which were not significantly different from those in the presence of NaHS (V~1/2~: 18.3 ± 1.2 mV, slope factor 20.2 ± 1.2) (*P* = NS; *n* = 6). In contrast, NaHS significantly influenced the steady-state inactivation of I~to~ ([Fig. 2](#fig02){ref-type="fig"}G). When fitted to Boltzman function, I/I~max~=1/\[1 + exp(V~T~ − V~1/2~/κ)\], the half-maximum inactivation voltage (V~1/2-inact~) and slope factor under control condition were −53.6 ± 1.2 mV and 9.08 ± 1.1, respectively, which were significantly different from those in the presence of NaHS (V~1/2-inact~: −71.1 ± 3.1 mV, slope factor 14.7 ± 2.4) (*P* \< 0.05; *n* = 6). Furthermore, recovery of I~to~ from inactivation was analysed by delivering two identical 500 ms depolarizing pulses from −80 to +60 mV and varying the interpulse from 50 to 3500 ms. Addition of NaHS shifted the curve right and increased the half-recovery time of I~to~ from of 461.7 ± 57 to 1218.2 ± 49 ms. (*P* \< 0.01; *n* = 6) ([Fig. 2](#fig02){ref-type="fig"}H), confirming inhibition of NaHS on the kinetic property of I~to~ channel recovery. Furthermore, these properties of I~to~ were similar to those reported in human ventricular fibroblasts \[[@b15]\].

The inhibitory effect of NaHS on I~to~ was further confirmed in the presence of NS5806 (10 μM), a specific opener of I~to~ \[[@b17]\] ([Fig. 2](#fig02){ref-type="fig"}I). The I~to~ currents were elicited with clamp pulses at +40 mV from a holding potential of −80 mV. Compared with baseline (18.8 ± 0.85 pA/pF), peak current density significantly increased (24.9 ± 1.5 pA/pF; *P* \< 0.05; *n* = 6) after the addition of NS5806, but additional presence of NaHS (100 μM) returned the NS5806-stimulated currents to baseline levels (18.6 ± 0.6 pA/pF; *P* \< 0.01; *n* = 6) ([Fig. 2](#fig02){ref-type="fig"}J). After exposure to NS5806 (10 μM), inactivation of I~to~ was significantly subdued, as reflected by an expansion in time constant (τ, from 8.6 ± 0.2 to 13.6 ± 0.7 ms at +30 mV, *P* \< 0.05; *n* = 6). However, addition of 100 μM NaHS returned the time constant to 10.1 ± 0.9 ms at +30 mV in the presence of 10 μM NS5806 ([Fig. 2](#fig02){ref-type="fig"}K), confirming inhibition of H~2~S on I~to~ current.

Besides BK~Ca~ and I~to~ currents, an inward rectifier current activated by hyperpolarization voltage steps on a holding potential of −40 mV that was sensitive to Ba^2+^ (0.5 mM) was found, indicating the presence of IK~ir~ inward current (28%; 28/309 cells) in the atrial fibroblasts ([Fig. 3](#fig03){ref-type="fig"}A). Exposure of atrial fibroblasts to 100 μM NaHS reduced the peak current density of IK~ir~ ([Fig. 3](#fig03){ref-type="fig"}B). The inhibitory effects occurred within 1 min., reached saturation at 10 min. and could not be washed out ([Fig. 3](#fig03){ref-type="fig"}C). NaHS showed a voltage-dependent suppression of the IK~ir~ current on the I--V curve from −4.4 ± 0.1 pA/pF to −3.0 ± 0.1 pA/pF at −110 mV (*P* \< 0.05; *n* = 6) ([Fig. 3](#fig03){ref-type="fig"}D) and a dose-dependent inhibition of peak current density with an IC~50~ of 78.9 μM ([Fig. 3](#fig03){ref-type="fig"}E).

![Effect of NaHS on IK~ir~ currents in human atrial fibroblasts. (**A**) inwardly rectifying voltage-dependent currents were suppressed by Ba^2+^ (0.5 mM). Ba^2+^-sensitive I--V relationships of the membrane currents of typical IK~ir~. (**B**) IK~ir~ traces recorded in the absence and presence of NaHS (100 μM). (**C**) Time course of IK~ir~ current inhibition after addition of NaHS (100 μM). (**D**) Mean I--V relationship of peak I~to~ current in the absence and presence of NaHS (100 μM) (\**P* \< 0.05 *versus* control). (**E**) A concentration response curve of NaHS-induced inhibition on IK~ir~ (\**P* \< 0.05; \*\**P* \< 0.01; *n* = 6).](jcmm0017-1345-f3){#fig03}

A minority of the atrial fibroblasts (1%; 1/54 cells) were found to exhibit inward currents with 50 ms voltage steps between −60 and +70 mV from −80 mV holding potential in 10 mV increments that resembled sodium current, indicating that K^+^ currents represent the major ionic species in human atrial fibroblasts.

H~2~S inhibits proliferation of atrial fibroblasts *via* suppression of I~to~ currents and gene expression
----------------------------------------------------------------------------------------------------------

Inhibition of BK~Ca~ channel by paxilline, but not Na channel, has been reported to suppress proliferation of ventricular fibroblasts previously \[[@b18]\]. We investigated whether inhibition of the major K^+^ currents of BK~Ca~ and I~to~ by H~2~S similarly affected atrial fibroblast proliferation. Cell proliferation was found to be dose-dependently suppressed by paxilline (BK~Ca~ inhibitor), 4-AP (I~to~ inhibitor) and Ba^2+^ (IK~ir~ inhibitor) ([Fig. 4](#fig04){ref-type="fig"}). Similarly, NaHS at 100, 300, 500 μM reduced cell proliferation by 33.1 ± 4.2%, 43.7 ± 3.1%, 58.4 ± 6.2%, respectively (\**P* \< 0.05; \*\**P* \< 0.01 *versus* vehicle control; *n* = 10) without significant apoptotic effect observed at 300 μM ([Fig. 4](#fig04){ref-type="fig"}B). While naringenin (100 μM) had no effect on cellular proliferation, NS5806 (100 μM) enhanced fibroblast proliferation by 9.1 ± 5.0% (*P* \< 0.05; *n* = 10). However, NaHS (100 μM) reduced cellular proliferation by 29.1 ± 5.8% (*P* \< 0.01; *n* = 10) and 23.1 ± 4.8% (*P* \< 0.05; *n* = 10) in the presence of naringenin (100 μM) and NS5806 (100 μM), respectively, confirming additive inhibitory effects of H~2~S on BK~Ca~ and I~to~ currents in reducing cellular proliferation ([Fig. 4](#fig04){ref-type="fig"}C and D).

![Effect of ion channel modulators on cell proliferation and apoptosis of human atrial fibroblasts. (**A**) Cell proliferation was assessed by BrdU assay in cells treated with Paxilline (0.3--3 μM), 4-AP (0.3--1 mM), Ba^2+^ (0.3--1 mM) or NaHS (100--500 μM) (\**P* \< 0.05; \*\**P* \< 0.01 *versus* basal levels; *n* = 10). (**B**) NaHS (1--300 μM) exerts no significant cellular apoptosis effect on cultured human atrial fibroblasts. (**C**) NaHS reverses fibroblast proliferation induced by Naringenin (Nari; BK~Ca~ opener, ^\#^*P* \< 0.05 *versus* Nari alone). (**D**) NaHS suppresses cellular proliferation induced by NS5806 (I~to~ opener, \**P* \< 0.05 *versus* basal levels; ^\#\#^*P* \< 0.01 *versus* NS5806 alone; *n* = 10).](jcmm0017-1345-f4){#fig04}

K~ATP~ channel has been reported to affect cellular proliferation \[[@b19]\]. However, modulation of K~ATP~ channel (30%; 22/73 cells) ([Fig. 5](#fig05){ref-type="fig"}A and B) and Kir6.2 (responsible for K~ATP~) gene expression ([Fig. 5](#fig05){ref-type="fig"}C) by H~2~S while confirming its role in enhancing current density, failed to show any appreciable effect on proliferation of our atrial fibroblasts. The K~ATP~ currents were elicited from voltage-clamped at the holding potential of −40 mV, voltage ramps were applied every 9 sec. from −120 mV to +60 mV at 20 mV/sec. and subsequently ramps to −40 mV at −100 mV/sec. Consistently, activation of the K~ATP~ channel by 30 μM pinacidil (specific channel enhancer) or its inhibition by 100 μM glibenclamide (specific channel inhibitor) did not significantly affect cellular proliferation despite the observed drastic modulation of current density ([Fig. 5](#fig05){ref-type="fig"}D and E). Down-regulation of fibroblast growth was observed only in the additional presence of NaHS with glibenclamide (19.9 ± 2.9% reduction *versus* control; *P* \< 0.01; *n* = 4) or NaHS with pinacidil (22.5 ± 4.2% reduction *versus* control; *P* \< 0.05; *n* = 4), suggesting that H~2~S inhibition of proliferation was independent of its modulating role of K~ATP~ channel in atrial fibroblasts.

![Effect of NaHS on K~ATP~ channels. (**A**) Superimposed K~ATP~ current traces recorded in the absence and presence of NaHS (100 μM), pinacidil (30 μM) and glibenclamide (100 μM) (*n* = 6 in each group). (**B**) Graph representation of mean values of K~ATP~ current in the absence and presence of NaHS (100 μM), pinacidil (30 μM) and glibenclamide (100 μM) (\**P* \< 0.05; \*\**P* \< 0.01 *versus* basal levels). (**C**) RT-PCR micrographs showing effect of 100 μM NaHS on Kir6.2 expression in atrial fibroblasts. Summary data displaying effect of NaHS on Kir6.2 expression. (\*\**P* \< 0.01 *versus* basal levels; *n* = 4). (**D** and **E**) Cell proliferation was assessed in cells treated with glibenclamide (1--100 μM), pinacidil (1--100 μM) in the absence and presence of NaHS (100 μM). (\**P* \< 0.05; \*\**P* \< 0.01 *versus* basal levels; *n* = 4).](jcmm0017-1345-f5){#fig05}

Gene expression showed that H~2~S reduced the mRNA level of KCa1.1 (responsible for BK~Ca~), Kv4.3 (responsible for I~to~), Kir2.1 (responsible for IK~ir~) in TGF-β1--stimulated fibroblasts by 42.3 ± 5.1% (*P* \< 0.05; *n* = 4), 76.9 ± 3.5% (*P* \< 0.01; *n* = 4), 90.8 ± 4.7% (*P* \< 0.01; *n* = 4), respectively, at 12 hrs after addition of NaHS ([Fig. 6](#fig06){ref-type="fig"}A--D). Furthermore, pre-treatment with NaHS decreased mRNA level of Kv4.3 by 21.6 ± 2.2% (*n* = 4; *P* \< 0.05 *versus* basal levels), but not that of KCa1.1 and Kir2.1. Furthermore, NaHS enhanced production of endogenous H~2~S by enhancing cystathionine γ--lyase (CSE) mRNA levels and maintaining its expression even in the presence of D,L-propargylgylcine (PPG), a potent inhibitor of CSE ([Fig. 6](#fig06){ref-type="fig"}E and F). These results indicated that H~2~S inhibited fibroblast proliferation by regulating Kv4.3 mRNA expression and inhibiting I~to~ current, possibly *via* an autocrine feedback mechanism.

![Effect of NaHS on ion channel and CSE expression. (**A**) RT-PCR micrographs of Kca1.1 (BK~Ca~), Kv4.3 (I~to~) and Kir2.1(Ik~ir~) expression in response to NaHS and transforming growth factor-β1 (TGF-β1). (**B**--**D**) Relative OD of PCR products. Each OD value is standardized to that of β-actin (\**P* \< 0.05; \*\**P* \< 0.01 *versus* basal levels; ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01 *versus* TGF-β1 alone; *n* = 4). (**E**) RT-PCR micrograph showing the expression of CSE in response to PPG (3 mM) and NaHS (100 μM). (**F**) Summary data displaying effect of NaHS on CSE expression in the absence and presence of 3 mM PPG (\*\**P* \< 0.01 *versus* basal levels; ^\#\#^*P* \< 0.05 *versus* PPG alone; *n* = 5).](jcmm0017-1345-f6){#fig06}

H~2~S inhibits TGF-β1--induced differentiation of atrial fibroblasts to myofibroblasts
--------------------------------------------------------------------------------------

Transforming growth factor-β1 and Angiotensin II (Ang II) as the major mediators of fibroblast proliferation and their differentiation towards myofibroblasts in atrial fibrosis \[[@b20], [@b21]\] were consistently shown to promote proliferation of atrial fibroblasts in our study ([Fig. 7](#fig07){ref-type="fig"}A). Additional presence of NaHS decreased TGF-β1-- (1 ng/ml), Ang II- (100 nM) and 20% FBS-induced fibroblast proliferation by 50.1 ± 4.3% (*P* \< 0.01; *n* = 10), 42.1 ± 5.7% (*P* \< 0.01; *n* = 10) and 21.2 ± 3.4% (*P* \< 0.05; *n* = 10), respectively, which suggested H~2~S as a potent inhibitor of cytokine-mediated fibroblast proliferation. Furthermore, NaHS (100 μM) decreased TGF-β1-(1 ng/ml)--induced fibroblast transformation into myofibroblasts whereby mRNA expression of α-SMA, a hallmark of fibroblast differentiation, was significantly down-regulated (34.1 ± 7.1% reduction *versus* TGF-β1 alone; *P* \< 0.05) ([Fig. 7](#fig07){ref-type="fig"}B), which was confirmed by reduced immunocytochemical α-SMA staining (percentage of α-SMA--positive cells, 47 ± 6% *versus* 90 ± 7%; *P* \< 0.01; *n* = 4) ([Fig. 7](#fig07){ref-type="fig"}C and D). Nevertheless, no significant change in α-SMA--containing stress fibres was observed after NaHS treatment alone (percentage of α-SMA--positive cells, 33 ± 4%; *n* = 4) as compared with standard cultured atrial fibroblasts (32 ± 7%; *n* = 4) in 10% FBS.

![H~2~S donor inhibits cytokine-induced fibroblast proliferation and transforming growth factor-β1 (TGF-β1)--mediated myofibroblast transformation. (**A**) Proliferation of atrial fibroblasts in response to TGF-β1 (1 ng/ml), Ang II (100 nM) and 20% FBS in the absence and presence of NaHS (100 μM) (\**P* \< 0.05; \*\**P* \< 0.01 *versus* basal levels; ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01 *versus* TGF-β1, Ang II and 20% FBS alone; *n* = 10). (**B**) RT-PCR micrograph showing the effect of TGF-β1 on α-smooth muscle actin (α-SMA) expression in atrial fibroblasts with and without 100 μM NaHS pre-treatment. Summary data displaying NaHS inhibition of TGF-β1--induced α-SMA expression (\**P* \< 0.05 *versus* basal levels; ^\#^*P* \< 0.05 *versus* TGF-β1 alone; *n* = 5). (**C**) Immunocytochemical staining of fibroblasts against α-SMA. Slides were counterstained with DAPI to visualize nuclei. Treatment of fibroblasts with 1 ng/ml TGF-β1 for 48 hrs induced a significant increase in expression of α-SMA that was attenuated by pre-treating fibroblasts with 100 μM NaHS for 48 hrs. Immunocytochemical data representative of four experiments in cells isolated from separate patient samples (*n* = 4). (**D**) Bar Graph representation of α-SMA--stained human fibroblasts. Cells were counted in 4 slides per group in 4 experiments (\*\**P* \< 0.01 *versus* vehicle control; ^\#\#^*P* \< 0.01 *versus* TGF-β1 alone).](jcmm0017-1345-f7){#fig07}

Discussion
==========

Multiple potassium channels are known to express in cardiac ventricular fibroblasts \[[@b15]\] and inhibition of BK~Ca~ current resulted in suppression of fibroblast proliferation \[[@b18]\]. Transient outward K^+^ current, I~to~, is present in neonatal rat cardiac fibroblasts (encoded by Kv1.4) \[[@b22]\] and human ventricular fibroblasts (encoded by Kv4.3) \[[@b15]\]. Similarly, Ba^2+^-sensitive inward rectifier K^+^ current (encoded by Kir2.1/Kir2.3) is present in human ventricular fibroblasts \[[@b15]\] and rat ventricular fibroblasts \[[@b23]\] whereby its modulation may have major significance in cardiac fibrosis. However, their roles in atrial fibroblasts which are more actively participating in cardiac fibrosis \[[@b24]\], are relatively not well understood.

We demonstrated that H~2~S dose-dependently inhibited BK~Ca~, I~to~ and IK~ir~ in human atrial fibroblasts within minutes, suggesting an acute modulation of H~2~S on such channels. The inhibitory effect of H~2~S on BK~Ca~, I~to~ and IK~ir~ was observed at 25--400 μM. The physiological levels of plasma H~2~S have been reported to be 50--160 μM in human brain \[[@b25]\] and 50--100 μM in human serum \[[@b26]\]. As NaHS dissolved in saline, one-third of the H~2~S exists as an undissociated gas, and the remaining two-third as the HS^−^ anion \[[@b27]\]. Therefore, the physiologically relevant concentration of H~2~S (25--400 μM) used in this study, which effectively blocked BK~Ca~, I~to~ and IK~ir~ *in vitro*, is likely to be attainable *in vivo*.

We found that NaHS attenuated naringenin-induced BK~Ca~ activation and decelerated the transition from closed to open state of the channel, suggesting a role for H~2~S in regulating BK~Ca~ channel kinetic and voltage sensitivity. However, NaHS had no effect on the half-maximum voltage activation, but shifted the steady-state inactivation curve to the left, indicating that the voltage-dependent steady-state inactivation kinetics of I~to~ channel were altered. Furthermore, NaHS markedly shifted the recovery curve of I~to~ to the right, indicating that H~2~S attenuated the recovery of I~to~ from inactivation. These results indicated that H~2~S inhibited I~to~ through facilitation of steady-state inactivation and attenuation of recovery from inactivation. In contrast to reported presence of sodium current in ventricular fibroblasts (61%) \[[@b15]\], we found relatively few cells (1%) with detectable sodium current. This is consistent with previous reported presence of fast sodium current only in atrial myofibroblasts, but not in undifferentiated fibroblasts \[[@b28]\] like those used in our study.

BK~Ca~ channels (encoded by KCa1.1) have been demonstrated to regulate proliferation of human cardiac ventricular fibroblasts \[[@b18]\] and endothelial cells \[[@b29]\]. Furthermore, inhibition of IK~ir~ current suppressed proliferation of endothelial cells \[[@b30]\]. Similarly, inhibition of BK~Ca~ (by paxilline), I~to~ (by 4-AP) and IK~ir~ (by Ba^2+^) currents resulted in a significant reduction in fibroblast proliferation in our study. Consistently, suppression of the K^+^ currents by NaHS inhibited atrial fibroblast proliferation in a dose-dependent manner. Furthermore, suppression of proliferation by NaHS in the presence of naringenin (channel opener of BK~Ca~) or NS5806 (channel opener of I~to~) suggested an additive inhibitory effect of H~2~S on BK~Ca~ and I~to~ channels in proliferation of atrial fibroblasts. Consistent with K~ATP~ channel--activating effect of H~2~S \[[@b11], [@b31]\], addition of NaHS recovered K~ATP~ channel activity from glibenclamide inhibition. Nevertheless, suppression of cellular proliferation by NaHS in the presence of glibenclamide (specific inhibitor of K~ATP~) or pinacidil (specific enhancer of K~ATP~) indicated that K~ATP~ channel was unlikely to be involved in proliferation of atrial fibroblasts. Consistently, H~2~S inhibition of lung fibroblast proliferation has been reported to be independent of K~ATP~ channel \[[@b32]\].

Consistent with electrophysiological findings on the presence of BK~Ca~, I~to~ and IK~ir~ potassium currents, RT-PCR confirmed expression of KCa1.1, Kv4.3 and Kir2.1 in atrial fibroblasts. Furthermore, H~2~S decreased Kv4.3 expression and significantly moderated TGF-β1--mediated enhanced expression of Kv4.3 as well as KCa1.1 and Kir2.1. Effect of NaHS (exogenous donor of H~2~S) on expression of cystathionine γ-lyase (CSE) that produces endogenous H~2~S is controversial, with reports of no effect in human airway smooth muscle cells \[[@b33]\] to inhibitory effect in mouse aortic smooth muscle cells \[[@b34]\]. However, in concordance with other reports \[[@b27], [@b35]\], our results showed that NaHS enhanced CSE expression and further sustained its expression in the presence of DL-PPG\[[@b27]\] that strongly inhibited expression of CSE.

Myofibroblasts characterized by increased α-SMA expression are abundant in cardiac fibrosis \[[@b36]\] that has been associated with TGF-β-mediated \[[@b20]\] and Ang II-mediated \[[@b21]\] atrial fibrillation. Preventing myofibroblast differentiation from proliferating fibroblasts has been an attractive target in limiting cardiac fibrosis. Inhibition of TGF-β1 function by anti--TGF-β1 antibodies reduced myofibroblasts and lessened fibrosis \[[@b37]\]. Hydrogen sulphide was found to inhibit TGF-β--induced transformation of MRC5 lung fibroblasts to myofibroblasts \[[@b32]\]. Consistently, our results showed that NaHS effectively reduced proliferation of atrial fibroblasts in response to TGF-β1, Ang II or FBS. Furthermore, NaHS ameliorated transformation towards myofibroblasts whereby α-SMA expression and their stress fibres were significantly suppressed, although causal role of potassium channels in such transformation remained to be ascertained.

In summary, our study provides evidence of major K^+^ channels in human atrial fibroblasts that share similar heterogenous expression as in human ventricular fibroblasts \[[@b15]\]. Hydrogen sulphide inhibits fibroblast proliferation probably through a combined modulation of BK~Ca~, I~to~, IK~ir~, but not K~ATP~, channels. Although roles of MAPK and ERK pathways in our atrial fibroblasts remain to be determined, they were implicated in H~2~S-mediated suppression of proliferation of vascular smooth muscle cells \[[@b38]\] and lung fibroblasts \[[@b32]\]. Both kinase pathways were linked to cell cycle progression in lung fibroblasts \[[@b39]\], which, in turn were reportedly regulated by Bk~Ca~ in human ventricular fibroblasts \[[@b18]\]. However, K~ATP~ was found to play no significant role in ERK-inhibiting effect of H~2~S \[[@b32]\], which may explain our observation in this study. Consistent with the observed beneficial effects of H~2~S on cardiac fibrosis *in vivo* \[[@b12], [@b13]\], our results suggested that such effects may be partly mediated *via* selective inhibition of K^+^ channels in atrial fibroblasts and suppression of their transformation to myofibroblasts. Such regulating role of H~2~S in atrial fibroblasts may have clinical value in targeting atrial fibrillation, which invariably linked to atrial fibrosis.
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Immunocytochemical staining against anti-collagen I (top panel) and anti-human fibroblast antibodies in human atrial fibroblasts. Scale bar: 25 μm
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Immunocytochemical staining of Bkca (Kv1.1), Ito (Kv4.3) and IKir (Kir2.1) channels in human atrial fibroblasts. Scale bar: 50 μm.
